Thrombotic thrombocytopenic purpura
Not recruitingStudy on the Safety of TAK-755, Rituximab, and Glucocorticoids for Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP)
Study on the Safety of TAK-755, Rituximab, and Glucocorticoids for Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP)
- Disease:Thrombotic thrombocytopenic purpura
- Substances:Apadamtase AlfaRituximab
Austria- Participants:18–64 years · 65+ years
- Substances:Apadamtase Alfa
- Sponsor:Takeda Development Center Americas Inc.













